Ruxolitinib
- Generic Name
- Ruxolitinib
- Brand Names
- Jakafi, Jakavi, Opzelura
- Drug Type
- Small Molecule
- Chemical Formula
- C17H18N6
- CAS Number
- 941678-49-5
- Unique Ingredient Identifier
- 82S8X8XX8H
- Background
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant act...
- Indication
Ruxolitinib is indicated for the treatment of the following conditions:
Topical ruxolitinib is indicated for:
- Associated Conditions
- Acute Graft-Versus-Host Disease (GVHD), Chronic Graft-Versus-Host Disease, Non-segmental Vitiligo, Post Polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis (Post-ET MF), Primary Myelofibrosis (PMF), High risk Myelofibrosis, Intermediate risk Myelofibrosis, Mild Atopic dermatitis, Moderate Atopic dermatitis, Refractory Polycythemia vera
- Associated Therapies
- -
KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera
- First Posted Date
- 2018-09-13
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Kartos Therapeutics, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT03669965
- Locations
- 🇭🇺
Békés Megyei Központi Kórház Pándy Kálmán Tagkórház, Gyula, Hungary
🇪🇸Hospital Universitario Virgen de la Victoria, Málaga, Spain
🇪🇸Hospital Universitario de Salamanca, Salamanca, Spain
Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2018-08-31
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 84
- Registration Number
- NCT03654768
- Locations
- 🇺🇸
Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
🇺🇸Anchorage Radiation Therapy Center, Anchorage, Alaska, United States
🇺🇸Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States
Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic Glucocorticoids
- First Posted Date
- 2018-08-06
- Last Posted Date
- 2023-10-05
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 49
- Registration Number
- NCT03616184
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
Ruxolitinib Plus LVP in Patients With R/R ETP-ALL
- Conditions
- Interventions
- First Posted Date
- 2018-08-03
- Last Posted Date
- 2018-08-03
- Lead Sponsor
- Sichuan University
- Target Recruit Count
- 12
- Registration Number
- NCT03613428
Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors
- Conditions
- Interventions
- First Posted Date
- 2018-08-01
- Last Posted Date
- 2024-11-04
- Target Recruit Count
- 41
- Registration Number
- NCT03610971
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸Emory -Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Memorial Sloan Kettering - Bergen, Montvale, New Jersey, United States
Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Drug: RuxolitinibDrug: CyclophosphamideDrug: CytarabineDrug: MercaptopurineDrug: VincristineDrug: PegaspargaseDrug: RituximabDrug: Methotrexate (Intrathecal Administration)Drug: Methotrexate (Intravenous Administration)Drug: DexamethasoneDrug: DoxorubicinDrug: ThioguanineDrug: Methotrexate Oral Product
- First Posted Date
- 2018-06-27
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 15
- Registration Number
- NCT03571321
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
The Role of Ruxolitinib in Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Neoplasm
- Conditions
- Interventions
- First Posted Date
- 2018-06-15
- Last Posted Date
- 2020-03-19
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 17
- Registration Number
- NCT03558607
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷Seoul National University Bundang Hospital, Seongnam, Korea, Republic of
Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia
- First Posted Date
- 2018-05-03
- Last Posted Date
- 2020-09-01
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT03515200
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2018-05-02
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT03514069
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease
- First Posted Date
- 2018-04-09
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 45
- Registration Number
- NCT03491215
- Locations
- 🇪🇸
Novartis Investigative Site, Madrid, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.